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Abstract
Background: Lynch syndrome (LS) is the most common form of inherited predisposition to colorectal cancer
(CRC), accounting for 2-5% of all CRC. LS is an autosomal dominant disease characterized by mutations in the
mismatch repair genes mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), postmeiotic segregation increased 1
(PMS1), post-meiotic segregation increased 2 (PMS2) and mutS homolog 6 (MSH6). Mutation risk prediction models
can be incorporated into clinical practice, facilitating the decision-making process and identifying individuals for
molecular investigation. This is extremely important in countries with limited economic resources. This study aims
to evaluate sensitivity and specificity of five predictive models for germline mutations in repair genes in a sample
of individuals with suspected Lynch syndrome.
Methods: Blood samples from 88 patients were analyzed through sequencing MLH1, MSH2 and MSH6 genes. The
probability of detecting a mutation was calculated using the PREMM, Barnetson, MMRpro, Wijnen and Myriad
models. To evaluate the sensitivity and specificity of the models, receiver operating characteristic curves were
constructed.
Results: Of the 88 patients included in this analysis, 31 mutations were identified: 16 were found in the MSH2
gene, 15 in the MLH1 gene and no pathogenic mutations were identified in the MSH6 gene. It was observed that
the AUC for the PREMM (0.846), Barnetson (0.850), MMRpro (0.821) and Wijnen (0.807) models did not present
significant statistical difference. The Myriad model presented lower AUC (0.704) than the four other models
evaluated. Considering thresholds of ≥ 5%, the models sensitivity varied between 1 (Myriad) and 0.87 (Wijnen) and
specificity ranged from 0 (Myriad) to 0.38 (Barnetson).
Conclusions: The Barnetson, PREMM, MMRpro and Wijnen models present similar AUC. The AUC of the Myriad
model is statistically inferior to the four other models.
Background
Lynch syndrome (LS) is the most common form of inher-
ited predisposition to colorectal cancer (CRC), account-
ing for 2-5% of all CRC [1]. Colorectal cancer in LS
differs from sporadic cases by an earlier age of diagnosis
(mean age approximately 44 years), a predominance of
proximally-sited colon cancers (60-70%) and an increased
propensity to synchronous or metachronous CRCs (25%)
[2,3]. Individuals with LS have an 80% probability of
developing CRC at 65 years, and they are at an elevated
risk of developing a second primary CRC [4] as well as at
an increased risk for extra-colonic malignancies, includ-
ing endometrial, gastric, small bowel, urological tract,
ovary, pancreas and brain cancer [5].
Family history has been the primary method for iden-
tifying patients at risk. The Amsterdam criteria, the first
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based on the presence of: (a) three or more relatives
with CRC, one of whom is the first-degree relative of
the other two; (b) cancer in at least two generations of
the same family; and (c) at least one cancer case diag-
nosed before the age of 50 [6]. These criteria, later,
evolved to become the Amsterdam II criteria, which
included extracolonic malignancies, such as endometrial,
small bowel, renal pelvic and ureter cancers [7]. The
Amsterdam criteria I/II, although specific, showed little
sensitivity (probability that a test result will be positive
when a disease is present [8]), which led to the estab-
lishment of the Bethesda guidelines, which helped the
identification of individuals who should be considered at
risk and need further evaluation of microsatellite
instability (MSI) and genetic testing [9,10]. The Bethesda
criteria showed to be more sensitive, but its specificity
(probability that a test result will be negative when the
disease is not present [8]) decreased substantially.
LS is an autosomal dominant disease characterized by
mutations in the mismatch repair genes mutL homolog
1 (MLH1), mutS homolog 2 (MSH2), postmeiotic segre-
gation increased 1 (PMS1), post-meiotic segregation
increased 2 (PMS2) and mutS homolog 6 (MSH6)
[7-11]. Germline abnormalities in MLH1 and MSH2
genes are found in more than 90% of LS mutation car-
riers [12].
The majority of MMR (mismatch repair) gene muta-
tions in LS patients cause truncations and loss of func-
tion of the affected polypeptide [13-15]. To date, over
513 different DNA alterations have been reported, the
majority of which are represe n t e db ys i n g l en u c l e o t i d e
substitutions, deletions or insertions [16]. However,
amino acid alterations comprise a significant proportion
of the mutations (~10% of MSH2 and ~30% of MLH1).
These types of alterations are better known as variants of
uncertain significance (VUS), often called unclassified
variants (UVs) [13-15]. Our ability to better select a non-
synonymous single-nucleotide polymorphism (nsSNP)
for an association study can be enhanced by first examin-
ing the potential impact an amino acid variant may have
on the function of the encoded protein with the use of
two innovative sequence homology-based programs, Sort
Intolerant from Tolerant (SIFT) and Polymorphism Phe-
notype (PolyPhen-2). SIFT uses sequence homology
among related genes and domains across species to pre-
dict the impact of all 20 possible amino acids at a given
position, allowing users to determine which nsSNPs
would be the most interesting to study. PolyPhen also
takes an evolutionary approach, but differs from SIFT in
that it predicts how damaging a particular variant may be
by using a set of empirical rules based on sequence, phy-
logenetic, and structural information [17].
Regarding social aspects, both economic and ethical,
pre-test genetic counselling performed by specialized
professionals is crucial for the discussion of benefits and
limitations of genetic testing [18], particularly in coun-
tries with limited resources. Since the estimated prob-
ability of mutation is an important component of
genetic counselling, models predicting the risk of muta-
tion can be incorporated into clinical practice, facilitat-
ing the decision-making process, and help to better
identify individuals for molecular investigation [19]. In
addition, prediction models can be used to identify indi-
viduals at high risk for cancer, who might benefit from
interventions, as well as to develop risk-benefit indexes
and to estimate the impact of the disease [19]. After the
first model published to evaluate the risk of chronic dis-
ease in 1976, numerous models related to the risk of
developing cancer have been created, and with the dis-
covery of the genetic susceptibility to breast cancer,
models to assess the likelihood of an individual carrying
a germline mutation have been widely used.
According to Freedman et al. [19] models should have
high sensitivity since it is assumed that they should
identify all mutation carriers. However, high specificity
is also important, especially from the clinical and eco-
nomical point of view, since it does not want to subject
individuals with a low likelihood to develop the disease
to the risks and costs of genetic testing.
Up until now, models predicting the risk of germline
mutations in patients with CRC were evaluated in conse-
cutive samples [20-27] and in patients at high risk due to
the positive family history [28-30]. In these studies, sam-
ples from Latin American populations were always under-
represented. Therefore, it is important to assess the
accuracy of the models currently available in Latin Amer-
ica populations, since they may have direct implications in
the clinical practice and genetic counselling.
This study aims to evaluate the sensitivity (probability
that a test result will be positive when the disease is pre-
sent) and specificity (probability that a test result will be
negative when the disease is not present) of five predictive
models for germline mutations in mismatch repair genes
in a sample of individuals with suspected Lynch syndrome.
Methods
Patient selection
The patients were recruited from two institutions in Sao
Paulo state, southeastern Brazil, who had participated in
a project that evaluated the Lynch syndrome profile in
South America. Eighty-eight individuals, whose clinical
information and heredogram were addressed, with col-
orectal cancer that fulfilled the Bethesda guidelines,
were included. This project was approved by the Institu-
tional Review Board at A.C. Camargo Hospital. After
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peripheral blood samples of subjects were collected.
The patients’ demographic, clinical and mutation
characteristics are shown in Table 1. Ethnicity was clas-
sified according to the patient’s self-report, according to
the recommendations of the IBGE (Brazilian Institute of
Geography and Statistics) [31], most patients self-
declared white (62.5%). Most patients were born in the
Southeast (76%). The average age at diagnosis of color-
ectal cancer was 42.37 years, and the mean age at diag-
nosis of endometrial cancer was 46.17 years. Of the
total, 21 individuals presented more that two primary
tumors.
Sequencing
Genomic DNA sequences of the MLH1, MSH2 and
MSH6 genes were obtained from the NCBI Nucleotide
database (NM_000249.2 NM_000251.1 and NM_000179,
respectively). Sequencing was performed in a 3130xl
Genetic Analyzer (Applied Biosystems).
The mutations found were confirmed in a second
sample through another PCR reaction with the use of
Platinum
® Taq DNA Polymerase High Fidelity (Invitro-
gen, São Paulo, Brazil), followed by sequencing.
For the interpretation and determination of the patho-
genicity of mutations, the following databases were con-
sulted: INSIGHT (International Society for Gastrointestinal
Hereditary Tumors); MMR Gene Unclassified Variants
Database; Mismatch Repair Genes Variant Database and
the Human Gene Database at the Institute of Medical
Genetics in Cardiff.
For the non-described variants: nonsense mutations,
small duplications, deletions and insertions have been
classified as pathogenic mutations, since they cause the
interruption of the protein reading frames; those muta-
tions that affect donor splicesites have also been classi-
fied as pathogenic since they affect the mRNA splicing
process, consequently affecting the protein structure.
For the pathogenicity prediction of missense variants,
two complementary algorithms were used: PolyPhen 2
(Polymorphism Phenotyping) and SIFT (Sorting Intolerant
from Tolerant). SIFT values range from 0 to 1: scores
≤ 0.05 were considered intolerant or substitution of dele-
terious amino acid, while scores above 0.05 were consid-
ered as tolerant. Structural changes levels were
determined by applying PolyPhen-2. PolyPhen-2 values
range from 0 to 3.37: variants with scores ≥ 2w e r ec o n s i d -
ered as “probably damaging,” scores between 1.50 and 1.99
indicated a “possibly damaging,” variant and scores 0 to
1.49 were considered as benign variants.
From 88 unrelated patients, 31 patogenic mutations
were identified, 11 for the first time [5]. The most fre-
quent mutation was c.2152 C > T; p.Gln718X in MSH2
that was observed in six subjects. All the other muta-
tions were observed once. From 15 MLH1 mutations, 3
were missense, 6 nonsense, 3 splice site and 3 frame-
shift. From 16 MSH2 mutations, one was missense, 10
nonsense, 1 splice site, and 4 frameshift.
Calculation of risk models
We consulted clinical information from patients’ records
and pedigrees to fit the risk prediction models. The prob-
ability of identifying a mutation was calculated by five
models: PREMM (Prediction of Mutations in MLH1 and
MSH2) [23]; Barnetson [21]; MMRpro [20]; Wijnen [22];
and Myriad [24] were calculated using the CancerGene
software program (The University of Texas Southwestern
Medical Center, Dallas, USA).
The PREMM model was developed from a multiple
logistic regression model in a cohort of 898 individuals,
and subsequently was validated in 1016 patients. This
model accounts for: the presence of CRC in the proband,
Table 1 Demographic, clinical and mutation
characteristics of the sample
Characteristic Category N (%)
Age at CRC diagnosis Under 30 yrs old 13 14.8
31-50 yrs old 54 61.4
Over 50 yrs old 21 23.9
Sex Female 58 65.9
Male 30 34.1
Ethnicity (self-reported) White 55 62.5
“Pardo"* 31 35.2
Non-available 2 2.3
Place of Birth Southeast 67 76.1
Northeast 12 13.6
South 3 3.4
North 2 2.3
Midwest 2 2,3
Colorectal tumor Separate 78 88.6
Synchronous 9 10.2
Metachronous 1 1.1
Extracolonic tumors in proband Endometrial 6 6.8
Breast 3 3.4
Stomach 2 2.3
Small intestine 2 2.3
Hepatic 1 1.1
Pelvis renal and
ureter
1 1.1
Ovary 1 1.1
Classification according to family
history
Bethesda Criteria 50 56.8
Amsterdam Criteria 38 43.2
Patogenic mutations None 57 64.8
MLH1 15 17.0
MSH2 16 18.2
*Those who declare with admixture or multiethnic origin
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occurrence of endometrial tumors and other Lynch syn-
drome-associated tumors in the proband; occurrence of
CRC in first-and second-degree relatives, the number of
affected relatives and the age at diagnosis of the youngest
individual; the presence of endometrial tumors and
Lynch syndrome-associated tumors in first-and second-
degree relatives [20].
The Barnetson model is based on the analysis of the
characteristics of 870 patients with less than 55 years of
age with CRC. This model enables the inclusion of
microsatellite instability and immunohistochemistry
(IHQ). The other variables included in this model are:
age at diagnosis of CRC; tumor location; occurrence of
synchronous and metachronous tumors; first-degree
relatives with CRC and endometrial cancer [21].
MMRpro uses a Bayesian method for calculating the
probability of mutation and also provides the risk of
CRC and endometrial cancer for non-affected indivi-
duals. Information used for the calculation of probability
includes: age of affected and non-affected relatives; age
at diagnosis of CRC; age at diagnose of endometrial can-
cer; result of microsatellite instability or IHQ if the
tumor is available; molecular diagnostic result if per-
formed [20].
The Wijnen or Leiden model was developed from the
analysis of 184 families with colorectal cancer. Variables
of this model are: age at diagnosis of CRC; presence of
endometrial tumor in family; fulfilment of Amsterdam
criteria [22].
Myriad elaborated mutation prevalence tables from
the analysis of 3410 individuals. The occurrence of CRC,
endometrial cancer and other tumors related to Lynch
syndrome are considered [24].
Statistical analysis
To evaluate the sensibility and specificity of the models,
receiver operating characteristic (ROC) curves were con-
structed by choosing cutpoints and computing the sensi-
tivity against specificity. The area under the ROC curve
describes the model discriminatory ability of distinguish-
ing carriers from non-carriers. An AUC (area under the
curve) of 0.5 indicates the absence of discriminatory abil-
ity, and 1 indicates a perfect discrimination [32,33]. To
compare the models, the method described by DeLong et
al. was used [34]: where areas under correlated ROC
curves are compared through a non-parametric approach
that applied generalized U-statistics on the covariance
matrix estimation.
Taking into consideration that genetic counselling
guidelines recommended genetic testing for breast can-
cer patients if a risk prediction model estimates a prob-
ability to detect a mutation ranges from 10% to 20%
[35], we calculate sensitivity and specificity for all mod-
els at 5%, 10%, 20% and 30%.
We also evaluated personal and family history charac-
teristics in our data that could predict mutation status.
Chi-square test was used for categorical data and stu-
dent-t test for numeric data in order to identify changes
in means of the subpopulations. Variables with a p-value
< 0.20 were selected for multiple analyses. Logistic
Regression Analysis was performed with calculation of
Odds Ratio (OR), considering the identification of patho-
genic mutation as the outcome. The p-value of 0.05 was
considered statistically significant. All statistical analysis
was performed using MedCalc version 11 and SPSS for
Windows version 15.
Results
Of the 38 patients who fulfilled the Amsterdam criteria,
23 presented mutations; 8 patients with Bethesda Guide-
lines presented mutations in the MLH1 or MSH2 genes.
The sensitivity of the Amsterdam criteria was 0.74 and
the specificity was 0.73 the sensitivity and specificity of
Bethesda Criteria were not calculated since it was the
inclusion criteria for this study.
Figure 1 presents the ROC curve. Table 2 presents the
AUC of models for pathogenic mutation and Table 3
the Pairwise comparison of ROC curves for MMR ger-
miline mutation. The AUC for the PREMM, Barnetson,
MMRpro and Wijnen models did not present significant
statistical difference. The Myriad model presented a
lower AUC than the four other models evaluated (p <
0.005) according to the method to compare ROC curves
described into Methods section.
Table 4 presents the sensitivity and specificity within 5%,
10%, 20% and 30% thresholds of the risk prediction models
for the MMR germiline mutations. Considering the ≥ 10%
the sensitivity among models ranges from 0.90 (MMRPre-
dict) to 0.96 (MMRPro, Myriad, Wijnen) and the specificity
ranges from 0.08 (MMRPro) to 0.54 (PREMM).
Table 5 presents results from AUC for risk prediction
models for MLH1 mutation and Table 6 the Pairwise
comparison for MLH1 mutation. Table 7 and 8 pre-
sents, respectively, regarding AUC and Pairwise compar-
ison for MSH2 mutation.
Table 9 presents the Logistic Regression Model for
identification of pathogenic mutation, considering those
personal and family history characteristics that were sig-
nificant at univariate analysis (data not shown). The
model presents a determination coefficient of 0.450 and
was statistically significant.
Discussion
The identification of MMR mutation carriers is relevant,
as there are individuals at high risk of developing cancer
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the early detection of cancer. However, the cost of
mutation detection by DNA sequencing is high, which
creates the need for adopting strategies in order to
reduce cost but maintain effectiveness. Although micro-
satellite instability (MSI) and immunohistochemistry
have been incorporated into clinical practice (despite
the fact that MSI is not a test widely available in Brazil)
risk prediction models can be valuable tools that could
be integrated in clinical practice.
According to the literature, this study presents a sig-
nificant sample of individuals from South America
[1,5,36-41]. The number of mutations identified in the
MSH2 gene was similar to the number of MLH1 muta-
tions found. It was also observed that the most frequent
extracolonic tumor in probands was endometrial tumor
followed by breast cancer.
Weitzel et al. [42] have pointed out risk prediction
model applications that could be perfectly adapted in
this situation: risk prediction models could help in the
elaboration of reports to health insurance companies in
order to get approvals for genetic testing; to provide rea-
listic expectations to the patient regarding a positive
result and to reinforce the absence of indication for
genetic testing when a low probability mutation
probability is calculated together with other screening
techniques, such as microsatellite instability. However,
for their use in the clinical practice, it is necessary that
accuracy and predictive ability is thoroughly evaluated,
since they may influence not only the adoption of a par-
ticular model but also its threshold.
In choosing the model for use in clinical practice three
main points should be considered: the availability of the
model; practical aspects in the management of the data;
and the model performance.
All models are available via the Internet or through
free software. When considering the advantages against
time, the PREMM and Barnetson models are the best
choice since they demand less time to be filled out.
Conversely, MMRpro and Wijnen are available at the
genetic counselling package CancerGene (CaGene) and
a family’s pedigree must be built, which is time consum-
ing. In addition, the information available on CaGene
must be stored and retrieved if novel elements from
family history appear, demanding recalculations. As
such, the structure and availability of human resources
also influence the choice of the model.
Regarding the analysis of accuracy, all models used in
this series presented AUC superior to 0.5. The largest
AUC was from the Barnetson model, but this difference
was not significant when compared to PREMM, MMRpro
and Wijnen. Both Barnetson and MMRpro use informa-
tion based on microsatellite instability and IHQ data,
which can increase accuracy. In this study, since tumor
samples of all subjects had not been taken, it was opted
not to include this information. The Myriad model pre-
sented an AUC inferior to the four other models, a result
also noticed by Monzon et al [28].
Since there is no consensus in the literature about which
t h r e s h o l ds h o u l db eu s e di nt h e s em o d e l si no r d e rt o
Figure 1 ROC Curve of risk prediction models for MMR germline mutations.
Table 2 AUC of risk prediction models, standard error
(SE) and 95% CI
Model AUC SE 95%CI Sensitivity Specificity
PREMM 0.846 0.0476 0.753-0.914 0.74 0.82
MMRPredict 0.850 0.0471 0.758-0.917 0.77 0.82
MMRpro 0.821 0.0506 0.725-0.895 0.74 0.82
Wijnen 0.807 0.0567 0.709-0.883 0.71 0.93
Myriad 0.704 0.0604 0.598-0.797 0.74 0.56
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cificity of the five models were calculated according to ≥
5%, ≥ 10%, ≥ 20% and ≥ 30% threshold. What is often
observed is a variation in sensitivity and specificity accord-
ing to the threshold and model used, which suggests that
the use of a single threshold for all models (e.g., 10%)
implies the alteration of both sensitivity and specificity
which could lead to a different detection mutation rate.
With the same threshold and similar sensitivities, as it
occurs with a 10% threshold and 0.90 sensitivity by the
Barnetson and PREMM models, the specificities are 0.33
and 0.58 respectively. When we consider threshold of 10%,
the best relationship between sensitivity and specificity
among models is regarding the PREMM model (sensitivity
90% specificity 54%).
As a consequence the healthcare professional must
consider the characteristics and the performance of each
model. The characteristics of each model should also be
discussed and considered prior implementation in a
genetic counselling practice.
The cost-effective analysis regarding Lynch Syndrome in
South America is a point of debate. These studies are still
at the initial stages. The evaluation of the costs will be of
crucial importance for the implementation of public poli-
cies for genetic testing and management of risk
individuals.
Considering the characteristics associated with a
pathogenic mutation in our sample, the histologic type
was the only that were not included in the models eval-
uated. It should be considered that this characteristic is
not always available at the time for genetic counselling,
therefore its inclusion could generate incomplete data.
The Brazilian population is extremely heterogeneous,
the result of five centuries of the integration of indivi-
duals from three continents:E u r o p e a n s ,A f r i c a n sa n d
Amerindians [43,44]. After colonization by the Portu-
guese, Brazil received a significant number of Africans.
With the end of slavery, Brazil received European immi-
grant groups, which contributed to a strong European
influence in the genome of the Brazilian citizen. Accord-
ing to Pena and colleagues [43], genetic variation among
Brazilians is so broad, that it should not be considered
as a group but at the individual level.
Table 3 Pairwise comparison of ROC curves for MMR germiline mutation
Models
Models MMRPro MMRPredict Myriad PREMM Wijnen
Dif* p Dif* p Dif* p Dif* p Dif* p
MMRPRo 0.028 0.524 0.117 0.017 0.024 0.479 0.014 0.762
MMRPredict 0.028 0.524 0.145 0.039 0.003 0.885 0.042 0.401
Myriad 0.117 0.017 0.145 0.003 0.141 0.005 0.103 0.134
PREMM 0.024 0.479 0.003 0.885 0.141 0.005 0.038 0.356
Wijnen 0.014 0.769 0.042 0.401 0.103 0.134 0.038 0.356
*Dif Difference between areas
Table 4 Sensitivity and specificity within the ≥ 5%, ≥
10%, ≥ 20% and ≥ 30% thresholds of the risk prediction
models for the MMR germline mutation
Models and threshold Sensitivity Specificity
MMRpro
≥ 5% 1.00 0.03
≥ 10% 0.96 0.08
≥ 20% 0.90 0.38
≥ 30% 0.87 0.52
MMRPredict
≥ 5% 0.93 0.38
≥ 10% 0.90 0.33
≥ 20% 0.83 0.70
≥ 30% 0.80 0.75
Myriad
≥ 5% 1.00 0
≥ 10% 0.94 0.31
≥ 20% 0.74 0.56
≥ 30% 0.10 0.92
PREMM
≥ 5% 0.98 0.28
≥ 10% 0.90 0.54
≥ 20% 0.67 0.85
≥ 30% 0.67 0.85
Wijnen
≥ 5% 1.00 0
≥ 10% 0.94 0.31
≥ 20% 0.74 0.56
≥ 30% 0.10 0.92
Table 5 AUC of risk prediction models for MLH1
mutation, standard error (SE) and 95% CI
Model AUC SE 95%CI Sensitivity Specificity
PREMM 0.721 0.0587 0.599-0.843 1 36.1
Barnetson 0.796 0.0562 0.696-0.874 0.87 0.61
MMRpro 0.742 0.0642 0.641-0.832 0.81 0.58
Wijnen 0.688 0.0892 0.533-0.741 0.56 0.76
Myriad 0.688 0.0632 0.580-0.782 0.81 0.51
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The molecular investigation was limited to direct
sequencing, and other techniques were not used for
molecular evaluation, such as MLPA, which could have
increased the number of identified mutations.
Conclusion
The Barnetson, PREMM, MMRpro and Wijnen mod-
els present similar AUC. The AUC of the Myriad
model is statistically inferior to the four other models.
When considering a threshold of ≥ 5%, the models
sensitivity varied between 1 (Myriad) and 0.87 (Wij-
nen) and the specificity ranged from 0 (Myriad) to
0.38 (Barnetson). With the threshold of ≥ 10%, the
models sensitivity ranged from 0.83 (Wijnen) to 0.96
(MMRpro) and specificity from 0.08 (MMRpro) to
0.54 (PREMM).
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Table 6 Pairwise comparison of ROC curves for MLH1 germiline mutation
Models
Models MMRPro MMRPredict Myriad PREMM Wijnen
Dif* p Dif* p Dif* p Dif* p Dif* p
MMRPRo 0.050 0.423 0.056 0.402 0.009 0.844 0.103 0.119
MMRPredict 0.050 0.423 0.108 0.104 0.003 0.885 0.042 0.401
Myriad 0.056 0.402 0.108 0.104 0.066 0.318 0.154 0.014
PREMM 0.009 0.844 0.003 0.885 0.066 0.318 0.112 0.052
Wijnen 0.103 0.119 0.042 0.401 0.154 0.014 0.112 0.052
*Dif Difference between areas
Table 7 AUC of risk prediction models for MSH2 mutation, standard error (SE) and 95% CI
Model AUC SE 95%CI Sensitivity Specificity
PREMM 0.794 0.0646 0.691-0.891 0.80 0.79
Barnetson 0.793 0.0764 0.650-0.839 0.80 0.69
MMRpro 0.794 0.0794 0.596-0.893 0.73 0.76
Wijnen 0.846 0.0499 0.754-0.914 0.93 0.78
Myriad 0.632 0.0733 0.522-0.732 0.93 0.26
Table 8 Pairwise comparison of ROC curves for MSH2 germiline mutation
Models
Models MMRPro MMRPredict Myriad PREMM Wijnen
Dif* p Dif* p Dif* p Dif* p Dif* p
MMRPRo 0.028 0.524 0.129 0.049 0.029 0.515 0.084 0.166
MMRPredict 0.028 0.524 0.037 0.363 0.092 0.120
Myriad 0.129 0.049 0.121 0.091 0.159 0.015 0.214 0.005
PREMM 0.029 0.515 0.037 0.363 0.159 0.015 0.055 0.158
Wijnen 0.084 0.166 0.092 0.120 0.214 0.005 0.055 0.158
*Dif Difference between areas
Table 9 Logistic regression model from personal and cancer family history characteristics associated with MLH1 or
MSH2 pathogenic mutation
Variable Category OR 95%CI p-value
CRC location (proband) Distal 1
Proximal 3.616 1.185-11.037 0.024
CRC Histological Type Tubular Adenocarcinoma 1
Mucinous Adenocarcinoma 3.974 1.160-13.613 0.028
Number of CRCs* 1.544 1.172-2.033 0.002
*Based on family history, considered as discrete variable
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